TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7630651

Group type: EXPERIMENTAL
Intervention: Bladder management by catheter (intermittent self‐catheterisation, indwelling urethral or suprapubic catheter)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterisation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Voiding by reflex or straining
Number of subjects: 70
Study: 2775152

Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rational emotive therapy (RET)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 340390

Group type: EXPERIMENTAL
Intervention: Teorema (420 mg/day for 21 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Teorema (210 mg/day for 21 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indometacin (150 mg/day for 21 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indometacin (75 mg/day for 21 days)
Number of subjects: 24
Study: 31054484

Group type: EXPERIMENTAL
Intervention: Evacetrapib (130 mg) plus atorvastatin (40 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo plus atorvastatin (40 mg)
Number of subjects: 100
Study: 29033985

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham group (placebo interventions)
Number of subjects: 50
Study: 26480546

Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture + SSRIs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication group (SSRIs only)
Number of subjects: 90
Study: 23834817

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (20 μg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VII (25 IU/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Activated factor VII
Number of subjects: 10
Study: 21747013

Group type: EXPERIMENTAL
Intervention: Nurse-administered behavioral management
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Nurse- and physician-administered medication management
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Combined intervention (behavioral + medication management)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 593
Study: 19187367

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Patient referral
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Postal testing kit (PTK)
Number of subjects: 467
Study: 16393297

Group type: EXPERIMENTAL
Intervention: Laxative (polyethylene glycol 3350 oral solution)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Laxative and tegaserod
Number of subjects: 48
Study: 14702232

Group type: EXPERIMENTAL
Intervention: Two-Way Communication Checklist (2-COM)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 134
Study: 12898306

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate combined with alfacalcidol (cyclical etidronate plus alfacalcidol 1 Ig daily continuously)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclical etidronate (oral etidronate 200 mg daily for 2 weeks every 3 months)
Number of subjects: 40
Study: 10193418

Group type: EXPERIMENTAL
Intervention: CD8+CD28+ T lymphocytes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CD8+CD28- T lymphocytes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CD38+ in CD8bright cells
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Triple therapy initiation
Number of subjects: 46
Study: 8525072

Group type: EXPERIMENTAL
Intervention: Steroid group (triamcinolone 200 mg i.v. within 4 h after trauma, followed by 3 x 40 mg/day i.v. for 4 days, and 3 x 20 mg/day i.v. for a further 4 days)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo group (injections without active drug)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Steroid group (in patients with focal lesion and Glasgow Coma Score < 8)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo group (in patients with focal lesion and Glasgow Coma Score < 8)
Number of subjects: 396
Study: 2271436

Group type: EXPERIMENTAL
Intervention: Atracurium 0.035 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium 0.07 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no atracurium)
Number of subjects: 80
Study: 6989226

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose load (1 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet containing 51% carbohydrate (sucrose or wheat starch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: OC-time interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak levels of glucose and insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin/glucagon ratio
Number of subjects: 0
Study: 31156199

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study: 28170104

Group type: EXPERIMENTAL
Intervention: Adapted mindfulness intervention plus treatment as usual (n = 20)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (n = 11)
Number of subjects: 31
Study: 26329790

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg (day 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (day 3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23484610

Group type: EXPERIMENTAL
Intervention: Extended rehabilitation program (ERP) for socially vulnerable patients
Number of subjects: 508

Group type: COMPARATOR
Intervention: Standard rehabilitation program (SRP) for socially vulnerable patients
Number of subjects: 508

Group type: COMPARATOR
Intervention: Standard rehabilitation program (SRP) for socially non-vulnerable patients
Number of subjects: 508
Study: 21085961

Group type: EXPERIMENTAL
Intervention: Cryoplasty
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional angioplasty
Number of subjects: 155
Study: 19245300

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 150/25 mg
Number of subjects: 722

Group type: COMPARATOR
Intervention: HCT 25 mg
Number of subjects: 722
Study: 17342794

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment applied for 1 week
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment applied for a further week (if no difference observed)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Topical corticosteroid (child's usual treatment)
Number of subjects: 96
Study: 15109518

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11822763

Group type: EXPERIMENTAL
Intervention: Therapeutic innovations tested in RCTs
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients enrolled in RCTs
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: RCTs analyzed according to intention-to-treat (ITT)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Power analysis (beta error) reported
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Adequate concealment of treatment allocation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Detailed description of patient withdrawals
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Double blind RCTs with appropriate methodology description
Number of subjects: 136
Study: 9260076

Group type: EXPERIMENTAL
Intervention: Ad lib smoking exposure
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 puffs exposure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Greater prior exposure (2, 6, or 12 puffs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 16
Study: 7942262

Group type: EXPERIMENTAL
Intervention: Laparoscopic Pomeroy tubal ligation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Minilaparotomy Pomeroy tubal ligation
Number of subjects: 44
Study: 30567590

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH; 32.0 °C-34.0 °C)
Number of subjects: 79
Study: 27229470

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection and Lidocaine (IS)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Corticosteroid with distension (ISD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 106
Study: 24487691

Group type: EXPERIMENTAL
Intervention: Tamoxifen (T)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Letrozole (L)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: 2-years Tamoxifen, 3-years Letrozole (TL)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: 2-years Letrozole, 3-years Tamoxifen (LT)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 424
Study: 22712469

Group type: EXPERIMENTAL
Intervention: DHEA replacement therapy (50 mg day(-1))
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 20576633

Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 39
Study: 17823766

Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic powder tablet)
Number of subjects: 60
Study: 16632234

Group type: EXPERIMENTAL
Intervention: Regular insulin sliding scale
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lispro insulin sliding scale
Number of subjects: 43
Study: 12810472

Group type: EXPERIMENTAL
Intervention: Intranasal furosemide
Number of subjects: 170

Group type: COMPARATOR
Intervention: No therapeutic treatment
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate
Number of subjects: 170
Study: 10980226

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8979159

Group type: EXPERIMENTAL
Intervention: Oral supplement of ascorbate, alpha‐tocopherol and beta‐carotene
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 7
Study: 1350882

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitrate therapy (patch removed at night, mean patch-off period 10 hours)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Continuous transdermal nitrate therapy (10 mg/24 hours)
Number of subjects: 85
Study: 3911965

Group type: EXPERIMENTAL
Intervention: Galphimia D6
Number of subjects: 164

Group type: COMPARATOR
Intervention: Galphimia dilution 10(-6)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 30590438

Group type: EXPERIMENTAL
Intervention: Moderate to high cumulative occupational physical activity (OPA) with low leisure-time physical activity (LTPA)
Number of subjects: 5243

Group type: EXPERIMENTAL
Intervention: High occupational physical activity (OPA) with low leisure-time physical activity (LTPA)
Number of subjects: 5243

Group type: COMPARATOR
Intervention: Low occupational physical activity (OPA) and high leisure-time physical activity (LTPA)
Number of subjects: 5243
Study: 29943445

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 26980905

Group type: EXPERIMENTAL
Intervention: Diode Laser Stapedotomy (DLS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Manual Stapedotomy (CMS)
Number of subjects: 60
Study: 24247229

Group type: COMPARATOR
Intervention: Anesthesiology program directors
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Surgery program directors
Number of subjects: 127
Study: 22714699

Group type: EXPERIMENTAL
Intervention: AMG 145 (monoclonal antibody inhibitor of PCSK9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20624650

Group type: EXPERIMENTAL
Intervention: Subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) therapy alone
Number of subjects: 65
Study: 17389534

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Paper-based decision aid
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control (no previsit education)
Number of subjects: 497
Study: 15625423

Group type: EXPERIMENTAL
Intervention: Glutamine supplemented enteral formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonsupplemented formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glycine supplemented enteral formula
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (including glutamine, glycine, and nonsupplemented formula)
Number of subjects: 80
Study: 12088809

Group type: EXPERIMENTAL
Intervention: 1.0 L/min fresh gas flow
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2.0 L/min fresh gas flow
Number of subjects: 56
Study: 9789512

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mock therapeutic touch
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25
Study: 7658482

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3000 mg of calcium carbonate providing 1200 mg elemental calcium)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 333
Study: 2611171

Group type: EXPERIMENTAL
Intervention: Domiciliary surveillance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 60
Study: 327092

Group type: EXPERIMENTAL
Intervention: Sulfonamide susceptibility testing using the disk-agar diffusion method
Number of subjects: 0
Study: 31783762

Group type: EXPERIMENTAL
Intervention: Home visit program (TKR-H)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-home visit program (TKR)
Number of subjects: 48
Study: 28222309

Group type: EXPERIMENTAL
Intervention: Gemcitabine-erlotinib-capecitabine (GEC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gemcitabine-erlotinib (GE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rash (grade ≥1)
Number of subjects: 120
Study: 26070976

Group type: EXPERIMENTAL
Intervention: PAG training (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Active control (n=11)
Number of subjects: 23
Study: 23722054

Group type: EXPERIMENTAL
Intervention: MR-proADM levels at 70 and 75 years
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Change in MR-proADM levels over time
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Baseline MR-proADM levels
Number of subjects: 1002
Study: 21988265

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: SHAM device
Number of subjects: 21
Study: 19232934

Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg/kg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 115

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 115
Study: 17825405

Group type: EXPERIMENTAL
Intervention: Mix A (sodium benzoate and artificial food colour mix A)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Mix B (sodium benzoate and artificial food colour mix B)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 15313860

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone sodium phosphate (1 mg/kg)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 11576055

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg bolus before morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg i.v. without propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol 0.3 mg/kg bolus followed by 1 mg/kg/h infusion during the study
Number of subjects: 40
Study: 9688371

Group type: EXPERIMENTAL
Intervention: 5000 IU i.m. HCG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10,000 IU i.m. HCG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10,000 IU s.c. HCG
Number of subjects: 18
Study: 8020523

Group type: EXPERIMENTAL
Intervention: iomeprol
Number of subjects: 100

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 100
Study: 2616932

Group type: EXPERIMENTAL
Intervention: Treatment A followed by Treatment B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B followed by Treatment A
Number of subjects: 0
Study: 319967

Group type: EXPERIMENTAL
Intervention: Pimozide 9.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine 12.5 mg
Number of subjects: 0
Study: 31521831

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study: 29571932

Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 86%‐94%
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 88%‐92%
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: A‐FiO2 with target range 89%‐91%
Number of subjects: 41
Study: 26812613

Group type: EXPERIMENTAL
Intervention: Aquaerobics program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aquaerobics group
Number of subjects: 36
Study: 23661583

Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters after one cycle of neoadjuvant chemotherapy
Number of subjects: 28
Study: 21126918

Group type: EXPERIMENTAL
Intervention: Individual face-to-face education and counseling intervention (45 min session)
Number of subjects: 2597

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2597
Study: 20040056

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) using student-teachers (STs) with limited training
Number of subjects: 151

Group type: COMPARATOR
Intervention: Staff-led group (SG) taught by ultrasound-experienced doctors
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Student-teachers (STs)
Number of subjects: 151
Study: 18591555

Group type: COMPARATOR
Intervention: Topotecan monotherapy 1.25 mg/m(2)/d
Number of subjects: 502

Group type: COMPARATOR
Intervention: Topotecan 1.0 mg/m(2) plus oral etoposide 50 mg/d
Number of subjects: 502

Group type: COMPARATOR
Intervention: Topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2) on day 1 and 600 mg/m(2) on day 8 every 3 weeks
Number of subjects: 502
Study: 15982747

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day (increased to 20 mg/day after 4 weeks)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 12162936

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined ACE inhibitor plus ARB therapy
Number of subjects: 0
Study: 10392386

Group type: EXPERIMENTAL
Intervention: Pacing at the right atrium (A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pacing at the RV paraseptal area (B), RV outflow tract (C), LV apex (D)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Multisite pacing (combination of sites)
Number of subjects: 37
Study: 8565157

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents with antiplatelet drugs (250 mg ticlopidine and 100 mg aspirin)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase I
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase II
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase III
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents in phase IV
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (all phases combined)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase I)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase II)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase III)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents (phase IV)
Number of subjects: 207
Study: 1756790

Group type: EXPERIMENTAL
Intervention: On-line visual feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly ordered trials with visual feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate blocks of trials with feedback and no-feedback
Number of subjects: 0
Study: 7051913

Group type: EXPERIMENTAL
Intervention: 50 mg of elemental zinc as zinc acetate (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 patients)
Number of subjects: 20
Study: 31515716

Group type: EXPERIMENTAL
Intervention: Children with preschool-onset depression
Number of subjects: 183

Group type: COMPARATOR
Intervention: Healthy group of young children
Number of subjects: 183
Study: 27494705

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy
Number of subjects: 41
Study: 30025257

Group type: EXPERIMENTAL
Intervention: Engineering instructions
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both engineering and transfer instructions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transfer instructions
Number of subjects: 64

Group type: COMPARATOR
Intervention: No instructions
Number of subjects: 64
Study: 25826291

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protein diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dietary advice delivery models
Number of subjects: 0
Study: 24868024

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg once per day plus paclitaxel 80 mg/m² once per week
Number of subjects: 261

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 261
Study: 23286539

Group type: COMPARATOR
Intervention: Ferrous sulphate (FS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 60